Outlook Therapeutics (OTLK) Shares Outstanding (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Shares Outstanding (Entity) of $81.8 million for Q1 2026, up 148.69% year-over-year from $32.9 million in Q1 2025, and up 26.77% quarter-over-quarter from $64.6 million in Q4 2025.
Outlook Therapeutics (OTLK) Shares Outstanding (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Shares Outstanding (Entity) for 12 consecutive years, with $81.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 148.69% year-over-year to $81.8 million; the TTM figure through Mar 2026 stood at $81.8 million (up 148.69% YoY), while the FY2025 annual figure was $34.8 million, up 87.59% from the prior year.
- Shares Outstanding (Entity) rose to $81.8 million in Q1 2026 per OTLK's latest filing, from $64.6 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $81.8 million in Q1 2026 and bottomed at $11.3 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $25.7 million across 5 years, with a median of $14.3 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) gained 1.4% — and 2025, when it soared 159.2%.
- Outlook Therapeutics' Shares Outstanding (Entity) stood at $12.8 million in 2022, then gained by 1.4% to $13.0 million in 2023, then surged by 91.39% to $24.9 million in 2024, then jumped by 159.2% to $64.6 million in 2025, then grew by 26.77% to $81.8 million in 2026.
- Business Quant data shows OTLK's Shares Outstanding (Entity) at $81.8 million in Q1 2026, $64.6 million in Q4 2025, and $34.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 136.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.84 Mn |
| Dec 31, 2025 | 60.21 Mn |
| Sep 30, 2025 | 34.80 Mn |
| Jun 30, 2025 | 36.96 Mn |
| Mar 31, 2025 | 30.87 Mn |
| Dec 31, 2024 | 24.23 Mn |
| Sep 30, 2024 | 18.55 Mn |
| Jun 30, 2024 | 23.23 Mn |
| Mar 31, 2024 | 14.27 Mn |
| Dec 31, 2023 | 13.01 Mn |
| Sep 30, 2023 | 12.51 Mn |
| Jun 30, 2023 | 12.84 Mn |
| Mar 31, 2023 | 12.83 Mn |
| Dec 31, 2022 | 11.37 Mn |
| Sep 30, 2022 | 10.60 Mn |
| Jun 30, 2022 | 11.02 Mn |
| Mar 31, 2022 | 10.95 Mn |
| Dec 31, 2021 | 9.41 Mn |
| Sep 30, 2021 | 7.63 Mn |
| Jun 30, 2021 | 8.42 Mn |